Navigating the future of 340B
The 340B Drug Pricing Program is at a crossroads, facing increased scrutiny, manufacturer restrictions, and ongoing legal battles.
Big news! Maxor is now VytlOne
Maxor Rebrands as VytlOne to Highlight Its Innovative Full-Service Pharmacy Solutions That Drive Revenue, Growth, and Better Outcomes Maxor National
How an Education Consortium Saved Money and Kept Their Members Happy
A large education consortium serving more than 85 school districts and 13,000 lives saved nearly $4.5 million in 2024.
PALs: A Vital Asset to Pharmacy Operations
Learn how the PALs program helped a local county health department to support pharmacy operations and improve outcomes.
Blog, Maxor
Rx to OTC: 5 drugs that went from prescription to over-the-counter
Are you curious about how some medicines, once available only by prescription, end up on your local pharmacy shelves for
Blog, Maxor
VytlOne and Maury Regional Health Expand Their Pharmacy Services Partnership
VytlOne, a leading provider of pharmacy solutions, is expanding its existing partnership with Maury Regional Health—a 255-bed, not-for-profit, vertically integrated
Blog, Maxor
Drug shortages: Q3 2025 Update
As of July 1, 226 active drug shortages are affecting the U.S. healthcare system, according to the American Society of
Navigating Pharmacy Benefits Effectively
Learn how to optimize your pharmacy benefits for better outcomes.
Improving Patient Outcomes Through Transition Care Management
When patients are discharged from the hospital without their prescribed medications, social determinants of health like prescription cost, transportation, or
How Recent 340B Changes Impact Specialty Pharmacies In 2025
The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown